A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus
Terminated · Phase 2 · NCT05123586
Conditions: Systemic Lupus Erythematosus
At a glance
- Research payments reported, 2025
- $1,413
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 85
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3361237 (drug), Placebo (drug)
- Dates
- Started 2022-03-07; completion 2023-12-29
- Results posted
- Yes
The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE). Study will last up to 34 weeks and may include up to 15 visits.
From ClinicalTrials.gov, last updated 2025-01-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1,413 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Desert Medical Advances $1,413
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.